Detalhe da pesquisa
1.
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal.
J Infect Dis
; 219(8): 1187-1197, 2019 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30407513
2.
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.
N Engl J Med
; 374(17): 1635-46, 2016 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-25629663
3.
Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebolavirus.
Cell Rep
; 29(9): 2537-2545.e3, 2019 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31775024
4.
Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine.
Vaccines (Basel)
; 7(2)2019 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31096710
5.
Activation-induced Markers Detect Vaccine-Specific CD4⺠T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials.
Vaccines (Basel)
; 6(3)2018 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-30065162
6.
Prime and target immunization protects against liver-stage malaria in mice.
Sci Transl Med
; 10(460)2018 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30257955
7.
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP.
NPJ Vaccines
; 3: 49, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30323956